NNNN
Anbio Biotechnology·NASDAQ
--
--(--)
--
--(--)
NNNN fundamentals
During H1 2025, Anbio Biotechnology (NNNN) reported revenue of 4.58M, a YoY change of -21.63%. Net income was 3.80M, a YoY change of 5.60%. Click to view the full income statement and explore the company's earnings performance.
Income Statement
FY,2021 | H1,2022 | FY,2022 | H1,2023 | FY,2023 | H1,2024 | FY,2024 | H1,2025 | TTM |
|---|
Start Date | Jan 1, 2021 | Jan 1, 2022 | Jan 1, 2022 | Jan 1, 2023 | Jan 1, 2023 | Jan 1, 2024 | Jan 1, 2024 | Jan 1, 2025 | -- |
End Date | Dec 31, 2021 | Jun 30, 2022 | Dec 31, 2022 | Jun 30, 2023 | Dec 31, 2023 | Jun 30, 2024 | Dec 31, 2024 | Jun 30, 2025 | -- |
Fiscal Year-End | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | -- |
Revenue | 4.43M -- | 17.84M -- | 23.54M +431.67% | 3.06M -82.85% | 6.71M -71.49% | 5.85M +91.19% | 8.19M +21.95% | 4.58M -21.63% | 6.92M -- |
Sales and Services Revenue | 4.43M -- | 17.84M -- | 23.54M +431.67% | -- -- | 6.71M -71.49% | 5.85M -- | 8.19M +21.95% | 4.58M -21.63% | 6.92M -- |
Cost of Revenue | 1.89M -- | 7.67M -- | 10.98M +482.08% | 1.26M -83.54% | 3.35M -69.48% | 1.94M +53.58% | 2.30M -31.37% | 351.94K -81.85% | 712.69K -- |
Cost of Goods and Services | -- -- | -- -- | 10.98M -- | -- -- | 3.35M -69.48% | 1.94M -- | 2.30M -31.37% | 351.94K -81.85% | 712.69K -- |
Gross Profit | 2.54M -- | 10.17M -- | 12.56M +394.25% | -- -- | 3.36M -73.25% | 3.91M -- | 5.89M +75.11% | 4.23M +8.24% | 6.21M -- |
Operating Expenses | 86.09K -- | 7.26K -- | 2.37M +2650.70% | -- -- | 1.40M -40.89% | 312.25K -- | 3.89M +177.87% | 865.43K +177.16% | 4.44M -- |
Selling, General and Administrative Expenses | 86.09K -- | 7.26K -- | 2.17M +2418.40% | -- -- | 1.27M -41.65% | 184.55K -- | 3.44M +171.55% | 734.13K +297.78% | 3.99M -- |
Research and Development Expenses | -- -- | -- -- | 200.00K -- | -- -- | 134.70K -32.65% | 127.70K -- | 454.23K +237.21% | 131.31K +2.82% | 457.83K -- |
Operating Income | 2.46M -- | 10.16M -- | 10.20M +315.15% | -- -- | 1.96M -80.77% | 3.60M -- | 2.00M +1.76% | 3.37M -6.42% | 1.76M -- |
Non-Operating Income (Loss) | 79.94K -- | -151.12K -- | -184.41K -330.70% | -- -- | 292.78K +258.76% | -1.72K -- | 377.48K +28.93% | 430.64K +25107.90% | 809.83K -- |
Gain (Loss) on Other Investment | -- -- | -- -- | -- -- | -- -- | -- -- | 0 -- | -- -- | -164.35K -- | -- -- |
Gain (Loss) on Foreign Currency Exchange | -- -- | -- -- | -262.22K -- | -- -- | 119.42K +145.54% | -140.19K -- | 20.47K -82.86% | 454.62K +424.29% | 615.27K -- |
Other Non-Operating Income (Loss) | 79.94K -- | -150.85K -- | 43.56K -45.50% | -- -- | 8.03K -81.58% | 0 -- | 19.50K +142.93% | 138 -- | 19.63K -- |
Net Interest Expense | -- -- | 272 -- | -34.25K -- | -- -- | -165.34K -382.79% | -138.46K -- | -337.51K -104.14% | -140.24K -1.28% | -339.28K -- |
Interest Expense | -- -- | 7.29K -- | 8.00K -- | -- -- | 0 -100.00% | -- -- | 0 -- | -- -- | -- -- |
Interest Income | -- -- | 7.02K -- | 42.24K -- | -- -- | 165.34K +291.37% | 138.46K -- | 337.51K +104.14% | 140.24K +1.28% | 339.28K -- |
Pretax Income From Continuing Operations | 2.54M -- | 10.01M -- | 10.01M +294.79% | 1.52M -84.81% | 2.25M -77.49% | 3.60M +136.52% | 2.37M +5.29% | 3.80M +5.60% | 2.57M -- |
Income Tax Expense | -- -- | -- -- | -- -- | -- -- | -- -- | 0 -- | -- -- | 0 -- | -- -- |
Net Income | 2.54M -- | 10.01M -- | 10.01M +294.79% | 1.52M -84.81% | 2.25M -77.49% | 3.60M +136.52% | 2.37M +5.29% | 3.80M +5.60% | 2.57M -- |
Net Income Attributable to Owners of the Company | 2.54M -- | 10.01M -- | 10.01M +294.79% | -- -- | 2.25M -77.49% | 3.60M -- | 2.37M +5.29% | 3.80M +5.60% | 2.57M -- |
Net Income Attributable to Common Stockholders | 2.54M -- | 10.01M -- | 10.01M +294.79% | -- -- | 2.25M -77.49% | 3.60M -- | 2.37M +5.29% | 3.80M +5.60% | 2.57M -- |
Total Comprehensive Income | -- -- | -- -- | -- -- | -- -- | -- -- | 3.60M -- | -- -- | 3.80M +5.60% | -- -- |
Total Comprehensive Income Attributable to Owners of the Company | -- -- | -- -- | 10.01M -- | -- -- | 2.25M -77.49% | 3.60M -- | 2.37M +5.29% | 3.80M +5.60% | 2.57M -- |
Basic EPS | 25.36K -- | 100.12K -- | 100.11K +294.79% | 6.51 -99.99% | 0.11 -100.00% | 0.09 -98.62% | 0.06 -45.45% | 0.09 -- | 0.06 -- |
Basic EPS from Continuing Operations | -- -- | -- -- | 100.11K -- | -- -- | 0.11 -100.00% | 0.09 -- | 0.06 -45.45% | 0.09 -- | 0.06 -- |
Diluted EPS | 25.36K -- | 100.12K -- | 100.11K +294.79% | 6.51 -99.99% | 0.11 -100.00% | 0.09 -98.62% | 0.06 -45.45% | 0.09 -- | 0.06 -- |
Diluted EPS from Continuing Operations | -- -- | -- -- | 100.11K -- | -- -- | 0.11 -100.00% | -- -- | 0.06 -45.45% | -- -- | -- -- |
You can ask Aime
What is Anbio Biotechnology's latest dividend and current dividend yield?What does Anbio Biotechnology do and what are its main business segments?What is the revenue and EPS growth rate for Anbio Biotechnology year over year?What were the key takeaways from Anbio Biotechnology's earnings call?What is Anbio Biotechnology's gross profit margin?What were the key takeaways from Anbio Biotechnology’s earnings call?Did Anbio Biotechnology beat or miss consensus estimates last quarter?What is the market's earnings forecast for Anbio Biotechnology next quarter?
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
